Liraglutide treatment for 26 weeks in women with PCOS significantly reduced liver fat content by 44%, visceral adipose tissue by 18%, and NAFLD prevalence by two-thirds (all P < .01).
RCT (n=72)
Double-blind
2:1
p-value: p=< .01
Women with polycystic ovary syndrome ( PCOS ) were treated with the GLP ‐1 receptor agonist liraglutide to investigate the effect on liver fat content, visceral adipose tissue ( VAT ) and the prevalence of nonalcoholic fatty liver disease ( NAFLD ). In a double‐blind, placebo‐controlled, randomized clinical trial 72 women with PCOS , with a BMI > 25 kg/m 2 and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks. Liver fat content was assessed by 1 HMR spectroscopy, VAT by MRI , body composition by DXA , and glucose metabolism by oral glucose tolerance test. Compared with placebo, liraglutide treatment reduced body weight by 5.2 kg (5.6%), liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two‐thirds (all P < .01). Sex‐hormone‐binding‐globulin ( SHBG ) levels increased by 19% ( P = .03), and free testosterone decreased by 19% ( P = .054). H b A 1c, fasting glucose and leptin were reduced (all: P < .05), whereas measures of insulin resistance, adiponectin and glucagon did not change. In conclusion, 26 weeks of liraglutide treatment in PCOS resulted in significant reductions in liver fat content, VAT and the prevalence of NAFLD .
Frøssing et al. (Thu,) conducted a rct in polycystic ovary syndrome (PCOS) (n=72). liraglutide vs. placebo was evaluated on liver fat content, visceral adipose tissue (VAT) and the prevalence of nonalcoholic fatty liver disease (NAFLD) (p=< .01). Liraglutide treatment for 26 weeks in women with PCOS significantly reduced liver fat content by 44%, visceral adipose tissue by 18%, and NAFLD prevalence by two-thirds (all P < .01).